0001485003-19-000076.txt : 20190905 0001485003-19-000076.hdr.sgml : 20190905 20190905172715 ACCESSION NUMBER: 0001485003-19-000076 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190826 FILED AS OF DATE: 20190905 DATE AS OF CHANGE: 20190905 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Anderson Kirstin CENTRAL INDEX KEY: 0001786554 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36296 FILM NUMBER: 191078042 MAIL ADDRESS: STREET 1: 245 FIRST STREET, SUITE 1800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sesen Bio, Inc. CENTRAL INDEX KEY: 0001485003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262025616 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET STREET 2: SUITE 1800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-444-8550 MAIL ADDRESS: STREET 1: 245 FIRST STREET STREET 2: SUITE 1800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Eleven Biotherapeutics, Inc. DATE OF NAME CHANGE: 20100223 3 1 wf-form3_156771881991462.xml FORM 3 X0206 3 2019-08-26 0 0001485003 Sesen Bio, Inc. SESN 0001786554 Anderson Kirstin C/O SESEN BIO INC 245 FIRST STREET - SUITE 1800 CAMBRIDGE MA 02142 0 1 0 0 Principal Accounting Officer Common Stock 32228 D Employee Stock Option (Right to Buy) 11.95 2024-09-02 Common Stock 2400.0 D Employee Stock Option (Right to Buy) 3.1 2025-05-20 Common Stock 2200.0 D Employee Stock Option (Right to Buy) 0.32 2026-01-28 Common Stock 2500.0 D Employee Stock Option (Right to Buy) 1.59 2027-10-03 Common Stock 15000.0 D Employee Stock Option (Right to Buy) 1.5 2028-04-09 Common Stock 8000.0 D Employee Stock Option (Right to Buy) 0.8285 2029-02-21 Common Stock 37000.0 D Represents shares purchased at various dates through 09/14/2017 through the exercise of vested stock options and participation in the Company's 2014 Employee Stock Purchase Plan. This option was granted on 09/03/2014. 25% of the shares subject to such option shall vest on the first anniversary of the date of grant of the option and an additional 6.25% of the shares underlying the option shall vest at the end of each successive three-month period thereafter until the fourth anniversary of the date of grant of the option. This option was granted on 05/21/2015. 1/24th of the shares subject to such option shall vest on the 21st day of each successive month until the second anniversary of the date of grant of the option. This option was granted on 01/29/2016. 6.25% of the shares subject to such option shall vest at the end of each successive three-month period until the fourth anniversary of the date of grant of the option. 469 vested options were exercised 12/06/2016 and are included above in common stock holdings. This option was granted on 10/04/2017. 25% of the shares subject to such option were immediately vested and an additional 25% of the shares underlying the option shall vest at the end of each successive six-month period until 18 months after the date of grant of the option. This option was granted on 04/09/2018. 6.25% of the shares subject to such option shall vest at the end of each successive three-month period until the fourth anniversary of the date of grant of the option. This option was granted on 02/21/2019. 6.25% of the shares subject to such option shall vest at the end of each successive three-month period until the fourth anniversary of the date of grant of the option. Form 3 filed as a result of designation as Principal Accounting Officer by the Board of Directors on 08/26/2019. Exhibit List: Exhibit 24: Power of Attorney /s/ Mark R. Sullivan General Counsel 2019-09-05 EX-24 2 sesn-limitedpowerofattorne.htm KIRSTIN ANDERSON POA Document


POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints the President and Chief Executive Officer, Chief Financial Officer, General Counsel and the Controller of Sesen Bio, Inc. (the “Company”), each as the undersigned’s true and lawful attorney-in-fact to:

(1)
execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of the Company, the undersigned’s application for EDGAR Access with the United States Securities and Exchange Commission (Form ID application);

(2)
execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of the Company, Forms 3, 4 and 5, in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(3)
do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to (A) complete and execute any such Forms 3, 4 or 5 (B), complete and execute any amendment or amendments thereto, and (C) timely file such forms with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(4)
take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of September 4, 2019.


/s/ Kirstin Anderson        
Kirstin Anderson